Comparaison du Ribociclib versus Palbociclib en traitement de deuxième ligne en association avec Fulvestrant dans le cancer du sein métastatique : un essai clinique randomisé

Shaaban et al. (Sun,) ont étudié cette question.

www.synapsesocial.com/papers/68e59d93b6db6435875384e8 — DOI: https://doi.org/10.31557/apjcp.2024.25.9.3039

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 214P Comparing ribociclib versus palbociclib as a second-line treatment in combination with fulvestrant in metastatic breast cancer: A randomised clinical trial· 2024
2. 223P Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) study· 2024 · 2 citations
3. The analysis of prescribing CDK4/6 inhibitors for patients with breast cancer in real clinical practice.· 2024 · 1 citations
4. A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort· 2025 · 2 citations
5. Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer· 2024 · 5 citations